GlassScriptPhysician profile
Jessica Steffey
NPI 1487453999
$1,551.12
in general payments reported to CMS, 2019-2025
20 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $401.32 | 2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $360.78 | 2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $198.53 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $100.51 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $78.38 | 2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $54.97 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $51.20 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.97 | 2025 | Xifaxan |
| Pfizer INC. | $32.40 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $30.57 | 2025 | Zilretta |
| Bioventus LLC | $30.48 | 2025 | Xcell |
| Inspire Medical Systems, INC. | $25.89 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.79 | 2025 | Caplyta |
| Abbott Laboratories | $22.88 | 2025 | Supera |
| Aimmune Therapeutics, INC. | $22.28 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $20.23 | 2025 | Ohtuvayre |
| Lundbeck LLC | $18.59 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $15.89 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $15.14 | 2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $11.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Steffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.